Eli Lilly (NYSE:LLY) is set to release its earnings report on Thursday, May 1, 2025. Traders focused on events or market actions may find insights in the past five, three, and one years’ performance. Over the past five years, LLY stock has consistently shown positive one-day returns, achieving a median of 4.5% and occasional single-day outperformance as high as 14.9%. These trends suggest that LLY remains a formidable performer in the stock market under new earnings announcements.
The company’s past five years have been marked by robust earnings growth, with sales rising by over 25%—oddly, but LLY has a long-term outlook. While the exact revenue numbers are not provided, the decade-over decade growth paints LLY as a strong performer in the face of earnings. This growth driver is primarily fueled by the steady demand for LLY’s rigorous obesity medication, Zepbound, which is projected to generate $2.2 billion in sales. Additionally, contributions from other drugs expected to match U.S. statistic on sales reach $3.75 billion.
About the company, LLY currently holds a market capitalization of $789 billion. This reflects the sustained success of the drug related to obesity and its dominance in the premium pharmaceutical sector. The company’s five-year trailing revenue is $45 billion, with operating profit at $18 billion and net income at $11 billion. These financial metrics underscore LLY’s strong performance and potential for long-term profitability.
For traders, spotting investment opportunities is key. The historical data suggests that LLY stock has historically performed well when earnings are announced. While this does not guarantee positive returns, it certainly indicates that profitability is a key driver of success for investors. Traders may consider strategies such as taking action before earnings day to leverage historical likelihood or evaluating immediate and medium-term returns after earnings announcements to shape future positioning.
Compared to all stocks, the Trefis High Quality portfolio is a safer bet for those seeking less volatility. Since its inception, the portfolio has closely matched the S&P 500, outperforming it by nearly 91%—signifying its superior risk-adjusted returns. While individual stocks perform faster, the Trefis portfolio offers more stability, making it an ideal choice for those prioritizing downside protection without compromising returns.
Earnings reactions come in different time horizons, from daily to several weeks, each reflecting investor expectations on the company’s financial health. A 1-day post-earnings return is critical. In the past five years, 8 out of 18 earnings data points were positive, with the median of 4.5% for positive returns and a lowest single-day return of -3.1%. The most recent three years showed a higher positive return rate (10 positive out of 12, median 4.5% versus -3% single-day). Over the longest span of five years, positive one-day returns were 44% of the time.
TL;DR: Eli Lilly (LLY) is poised for strong earnings, supported by increasing demand for its popular drug and solid financial metrics. Traders should look to take an action stance before earnings is finalized or monitor immediate and medium-term returns closely to assess potential gains. High Quality portfolios are recommended for those seeking consistency in performance with lower risk profiles.
